Trial reportEuropean journal of nuclear medicine and molecular imaging2020
Comparison of
Trial report in European journal of nuclear medicine and molecular imaging, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Theranostic Radiopharmaceuticals of Somatostatin Receptors for Patients with Neuroendocrine Tumors: Agonists Versus Antagonists-A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2025Pooled it
- Malignancy Detection Rates of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Trial
- Controversies in NEN: An ENETS position statement on the interchangeability of somatostatin receptor PET tracers.Journal of neuroendocrinology · 2026Review
- Gallium-Containing Agents for Tumor Diagnosis and Therapy: Current Status and Future Prospects.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- [EJNMMI physics · 2026Article
- Clinical Applications of Theranostics.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2026Review
- The molecular blueprint of targeted radionuclide therapy.Nature reviews. Clinical oncology · 2025Review
- Radionuclide-Labeled Biomaterials: A Novel Strategy for Tumor-Targeted Therapy.Biomimetics (Basel, Switzerland) · 2025Review
- Comparative analysis of positron emitters for theranostic applications based on small bioconjugates highlightingEJNMMI physics · 2024Article
- The Emergence of Somatostatin Antagonist-Based Theranostics: Paving the Road Toward Another Success?Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Article
- Immunostimulatory effects of a subcritical water extract ofBiomedical reports · 2023Article
- Relationships between uptake of [EJNMMI research · 2022Article
- Peptide Receptor Radionuclide Therapy.The Journal of clinical endocrinology and metabolism · 2022Article
- Production Review of Accelerator-Based Medical Isotopes.Molecules (Basel, Switzerland) · 2022Review
- Radiolabeled Somatostatin Analogs-A Continuously Evolving Class of Radiopharmaceuticals.Cancers · 2022Review
- Radiolabeled Somatostatin Analogues for Diagnosis and Treatment of Neuroendocrine Tumors.Cancers · 2022Review
- Review
- Advances in Molecular Imaging and Radionuclide Therapy of Neuroendocrine Tumors.Journal of clinical medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 2 countries.
Funding
Abstract
purposePaired imaging/therapy with radiolabeled somatostatin receptor (SSTR) antagonists is a novel approach in neuroendocrine tumors (NETs). The aim of this study was to compare tumor uptake of
methodsAs part of a prospective clinical trial, 20 patients with metastatic NETs underwent
resultsA total of 95 lesions were analyzed on
conclusionOur study shows that
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.